OctoPlus N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
11 okt 2007 - 23:53
Statutaire naam
OctoPlus N.V.
Titel
OctoPlus announces positive Phase IIa efficacy and tolerability results for Locteron in hepatitis C
Bericht
OctoPlus N.V. (Euronext: OCTO), the drug delivery and development company, announces today the successful completion of the Phase IIa clinical study with its lead product Locteron™, a controlled release interferon alfa product for the treatment of chronic hepatitis C (HCV).
Results from this study confirm Locteron’s potential to substantially improve patient care in HCV. Safety data from the study show a substantially improved tolerability profile for Locteron compared to other interferon products on the market or in development. Efficacy data from the study indicate Locteron’s strong antiviral effect, with 100% of the patients achieving early virologic response in the two highest dose groups. In addition, Locteron is a more convenient therapy than existing treatments due to its controlled-release profile, allowing for once every two weeks drug administration versus the current once a week regimen. OctoPlus is co-developing Locteron with its partner Biolex Therapeutics.
Datum laatste update: 19 december 2025